Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
The intraperitoneal (i.p.) administration of autologous spleen cells treated with recombinant interleukin-2 (IL-2) in vitro resulted in the rejection of C57BL/10ScSn (B10) skin grafts that had survived for 18 months on CBA/Ca mice tolerant to B10 alloantigens. Cytotoxic lymphocytes specific for the graft alloantigens, assayed by limiting dilution analysis, appeared after the breaking of this immunological tolerance, whereas they were not detectable in tolerant mice. In these mice the frequencies of precursor cytotoxic cells specific for third-party alloantigens were unaffected by the IL-2 treatment.
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2022 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
